Evidence map›Paper›PMID 31608656›Full record

ArticleJournal of diabetes science and technology2019

The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results.

Pau Herrero, Mohamed El-Sharkawy, John Daniels, Narvada Jugnee, Chukwuma N Uduku, Monika Reddy, Nick Oliver, Pantelis Georgiou

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Pau HerreroCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, UK.ORCID 0000-0002-7088-5807
Mohamed El-SharkawyCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, UK.
John DanielsCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, UK.
Narvada JugneeDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
Chukwuma N UdukuDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
Monika ReddyDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
Nick OliverDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
Pantelis GeorgiouCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, UK.
Imperial College London · GB

Funding

Wellcome TrustWellcome Trust 100921/Z/13/Z
6 · The paper itself

Abstract

backgroundArtificial pancreas (AP) technology has been proven to improve glucose and patient-centered outcomes for people with type 1 diabetes (T1D). Several approaches to implement the AP have been described, clinically evaluated, and in one case, commercialized. However, none of these approaches has shown a clear superiority with respect to others. In addition, several challenges still need to be solved before achieving a fully automated AP that fulfills the users' expectations. We have introduced the Bio-inspired Artificial Pancreas (BiAP), a hybrid adaptive closed-loop control system based on beta-cell physiology and implemented directly in hardware to provide an embedded low-power solution in a dedicated handheld device. In coordination with the closed-loop controller, the BiAP system incorporates a novel adaptive bolus calculator which aims at improving postprandial glycemic control. This paper focuses on the latest developments of the BiAP system for its utilization in the home environment.

methodsThe hardware and software architectures of the BiAP system designed to be used in the home environment are described. Then, the clinical trial design proposed to evaluate the BiAP system in an ambulatory setting is introduced. Finally, preliminary results corresponding to two participants enrolled in the trial are presented.

resultsApart from minor technical issues, mainly due to wireless communications between devices, the BiAP system performed well (~88% of the time in closed-loop) during the clinical trials conducted so far. Preliminary results show that the BiAP system might achieve comparable glycemic outcomes to the existing AP systems (~73% time in target range 70-180 mg/dL).

conclusionThe BiAP system is a viable platform to conduct ambulatory clinical trials and a potential solution for people with T1D to control their glucose control in a home environment.

Indexed as

Pancreas, ArtificialAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Equipment DesignHumansHypoglycemic AgentsInsulinSoftwareBlood GlucoseHypoglycemic AgentsInsulinartificial pancreasautomatic insulin deliverybio-inspired technologylow-power electronicstype 1 diabetes

Identifiers

PMID31608656
PMCPMC6835194
OpenAlexW2980000291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.